Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

ates, to protect the use of IL-17E in the treatment of these cancers, both alone and in combination with other chemotherapies.

Virulizin(R) stimulates production of the antitumor protein TNFalpha

The article titled "Virulizin(R), a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo." was published in the journal International Immunopharmacology (volume 7, issue 10, pages 1350-9).

The study revealed that treatment with Virulizin(R) resulted in a significant induction of the cytokine TNFalpha in tumors in a mouse model of malignant melanoma. Virulizin(R) also stimulated production of TNFalpha in human macrophages in vitro. Importantly, a direct relationship between TNFalpha production by Virulizin(R) and cytotoxic activity towards cancer cells was demonstrated.

TNFalpha is a protein that is produced by cells of the immune system, particularly macrophages, which then activate other immune cells to attack tumor cells. The anticancer properties of TNFalpha are well known, and have been studied in both preclinical and clinical settings. These new findings confirm initial studies indicating that TNFalpha can contribute to the antitumor mechanism of Virulizin(R).

About Virulizin(R)

Virulizin(R) is a novel biological response modifier (or immunotherapeutic agent) that stimulates a patient's immune system through several mechanisms, including the activation of macrophages and the infiltration of natural killer cells into tumors. In preclinical studies, Virulizin(R) has demonstrated potential high levels of antitumor activity against a number of cancer indications including pancreatic cancer. Virulizin(R) has been granted orphan drug status and fast track status from the United States FDA and orphan designation from the Marketing Authorization Application with the European Medical Evaluation Agency (EMEA). A drug that receives fast track designation must demonstrate that it is intend
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Fla., Dec. 14 Dyadic International, Inc. ... has extended its collaboration with The Scripps Research ... Scripps to re-annotate the genome of Dyadic,s patented ... is a continuation of the successful relationship between ... when Dyadic engaged Scripps to annotate the C1 ...
(Date:12/14/2009)... 14 The third edition of ... , published by the Infusion Nurses Society ... anthracycline extravasation.(1) Anthracyclines are a group of ... that have been used in the treatment of ... ,, According to the INS publication: ...
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 Lionbridge ... it has signed a new, three-year master ... company with products and services that serve ... agreement Lionbridge will become the sole provider ... which includes regulatory, marketing, training, human resources, ...
(Date:12/14/2009)... Mass., Dec. 14 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that, owing ... atrial fibrillation drug market will increase more than ... billion in 2018 in the United States, France, ... ,, The new Pharmacor report entitled Atrial ...
Breaking Biology Technology:Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2
... Carol Bartz Madison, Wis. Carol Bartz, ... University of Wisconsin Madison's Entrepreneur Hall of Fame ... in 1971. , ,The honor was bestowed by the ... School of Business. Before the luncheon awards ceremony, Bartz spent ...
... Madison, Wis. The Croquet Project ... Division of Information Technology (DoIT), the University ... Inc. of Glendale California, has announced the release of ... a new open-source software technology and peer-to-peer network architecture ...
... Madison, Wis. Virent , a University of ... $2 million grant from the Department of Energy for continued ... directly from water and sugar in a one-step process as ... could evade some of the problems of storing hydrogen, a ...
Other Biology Technology:Entrepreneurial Profile Carol Bartz, CEO of Autodesk, shares secrets of success 2UW-Madison releases open 3D collaboration environment 2
(Date:12/14/2009)... team of researchers from the Astrobiology Centre (INTA-CSIC) has ... essential to the formation of the most basic biological ... In order to carry out this study, published in ... recreated the chemical conditions of the early Earth. , ... in ammoniac solutions it produces hydrogen cyanide, a substance ...
(Date:12/14/2009)... MODA Technology Partners, a global software ... product testing for the Pharmaceutical industry, today announced ... third generation mobile data acquisition platform. The latest ... automate their regulated manufacturing processes. ,, MODA ... Fully-Configurable Test Methods: Each test method ...
(Date:12/13/2009)... Scientists have resolved a question about how a ... works using biosensors that reveal previously hidden components ... Although delusions and hallucinations characterize the illness, people ... recall information in a particular order, difficulties that ... or function well, said Lee Schroeder, a student ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2NASA researcher nets first measure of Africas coastal forests 9644 1NASA researcher nets first measure of Africas coastal forests 9644 2NASA researcher nets first measure of Africas coastal forests 9644 3NASA researcher nets first measure of Africas coastal forests 9644 4Fattah Advocates D C March for Healthcare By the Supporters of Reform with Public Option 54984 1ConnextionsHealth Introduces Turnkey Rapid Ramp Call Verification Solution 54979 1ConnextionsHealth Introduces Turnkey Rapid Ramp Call Verification Solution 54979 2ConnextionsHealth Introduces Turnkey Rapid Ramp Call Verification Solution 54979 3
... Can biofuels produced from non-food plant products like ... reality? Can plants be engineered to grow vaccines or ... researchers from Worcester Polytechnic Institute (WPI) and the Arkansas ... Life Sciences and Bioengineering Center at Gateway Park. , ...
... born without the ability to recognise voices has been reported in ... of a rare condition known as phonagnosia. The UCL team are ... have also grown up with the condition. , The ... Neuropsychologia , is of a woman who is unable to recognise ...
... month that it is funding a new research effort ... and whether it is possible to build ... The $2 million grant is one of six NSF ... research. The Illinois team will tackle the engineering, social, ...
Other Biology News:Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 2Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 3Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 4Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 5Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 6Are you phonagnosic? 2NSF funds research at Illinois on sustainable biofuels infrastructure 2NSF funds research at Illinois on sustainable biofuels infrastructure 3
BOND ELUT MATRIX-C18, 25 mg ...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Human Legumain Affinity Purified Polyclonal Ab...
Biology Products: